

Integra LifeSciences Schedules Conference Call for Friday, October 31 to Discuss Third Quarter 2003 Financial Results and Update Forward-Looking Financial Guidance

PLAINSBORO, N.J.--(BUSINESS WIRE)--Oct. 17, 2003--Integra LifeSciences Holdings Corporation (NASDAQ:IART) has scheduled a conference call for 9:00 AM EST on Friday, October 31 to discuss financial results for the third quarter ended September 30, 2003 and to update forward-looking financial guidance, including the expected impact of Integra's recent agreement to resume exclusive responsibility for the sales, marketing and distribution of the INTEGRA® Dermal Regeneration Template product in 2004. Financial results for the third quarter 2003 will be announced via a news release issued before the market opens on October 31.

The conference call will be hosted by Stuart Essig, President and Chief Executive Officer of Integra, and will be open to all listeners. Additional forward- looking information may be discussed in a question and answer session following the call.

Access to the live call is available by dialing 973-935- 2100 or through a webcast via a link provided on Integra's website at www.Integra-LS.com. Access to a replay is available through November 14 by dialing 973- 341-3080 (PIN 3609053) or through the webcast.

Integra LifeSciences Holdings Corporation is a diversified medical technology company that develops, manufactures, and markets medical devices for use in a variety of applications. The primary applications for Integra's products are neuro-trauma and neurosurgery, plastic and reconstructive surgery, and soft tissue repair. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. The Company has its corporate headquarters in Plainsboro, New Jersey, with manufacturing and research facilities located throughout the world.

CONTACT: Integra LifeSciences Holdings Corporation Maria Platsis, 609-936-2333 mplatsis@integra-ls.com John Bostjancic, 609-936-2239 jbostjancic@integra-ls.com

SOURCE: Integra LifeSciences Holdings Corporation